Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,182,493 papers from all fields of science
Search
Sign In
Create Free Account
LY517717
Known as:
LY 517717
, LY-517717
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Glycine
Piperazines
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Oral Anticoagulants in Development
B. Eriksson
,
D. Quinlan
Drugs
2012
Corpus ID: 46986086
Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of…
Expand
Review
2010
Review
2010
Successful applications of computer aided drug discovery: moving drugs from concept to the clinic.
T. Talele
,
Santosh A. Khedkar
,
A. C. Rigby
Current topics in medicinal chemistry
2010
Corpus ID: 21446235
Drug discovery and development is an interdisciplinary, expensive and time-consuming process. Scientific advancements during the…
Expand
Review
2009
Review
2009
New anticoagulants: focus on venous thromboembolism.
A. Gómez-Outes
,
R. Lecumberri
,
C. Pozo
,
E. Rocha
Current vascular pharmacology
2009
Corpus ID: 19076553
Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary…
Expand
Review
2008
Review
2008
Fragment-Based Approach to Drug Lead Discovery
D. Fattori
,
A. Squarcia
,
S. Bartoli
Drugs in R&D
2008
Corpus ID: 31676543
In the last 20 years the advent of new technologies, such as high-throughput screening (HTS) and combinatorial chemistry, has…
Expand
Review
2008
Review
2008
New oral anticoagulants in atrial fibrillation.
A. Turpie
European heart journal
2008
Corpus ID: 16452979
Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K…
Expand
Review
2007
Review
2007
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases
A. Turpie
Arteriosclerosis, thrombosis, and vascular…
2007
Corpus ID: 2998452
Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing…
Expand
Highly Cited
2007
Highly Cited
2007
A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement
G. Agnelli
,
S. Haas
,
Jeffrey S. Ginsberg
,
K. Krueger
,
A. Dmitrienko
,
J. Brandt
Journal of thrombosis and haemostasis : JTH
2007
Corpus ID: 33102639
Summary. Background: LY517717 is an oral direct inhibitor of activated factor X that is currently under clinical development.
Review
2006
Review
2006
Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery.
B. Eriksson
,
D. Quinlan
Drugs
2006
Corpus ID: 38154902
Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of…
Expand
Review
2006
Review
2006
Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases
D. Kubitza
,
S. Haas
Expert opinion on investigational drugs
2006
Corpus ID: 23276837
Novel anticoagulants to replace unfractionated heparins, low molecular weight heparins and vitamin K antagonists, are needed…
Expand
Review
2005
Review
2005
Small molecule coagulation cascade inhibitors in the clinic.
E. Saiah
,
Chris Soares
Current topics in medicinal chemistry
2005
Corpus ID: 35371062
Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE